This pooled analysis demonstrates similar clinical outcomes in metastatic colorectal cancer across diverse populations, suggesting potential refinements in trial eligibility criteria.
Key Points
This analysis aims to determine clinical outcomes in patients with metastatic colorectal cancer enrolled in phase I trials and identify important prognostic markers.
Retrospective review of medical records from two institutions (1999-2018, 2021-2025)
Data collection included demographics, clinical findings, responses, and overall survival
Univariate analyses using the Mantel-Cox test to evaluate survival outcomes
Analyzed data from 295 patients across 71 trials, with a median age of 59 years
Overall survival was 9 months, not significantly different across racial/ethnic groups (p=0.71)
Key predictors of worse overall survival included poor performance status (HR 2.665), 3 or more metastatic sites (HR 1.497), and high LDH (HR 1.751)